Holen Sie sich die Stockscreener-App
1.81
4.74%
-0.09
Handel nachbörslich:
1.83
0.02
+1.10%
Schlusskurs vom Vortag:
$1.90
Offen:
$1.91
24-Stunden-Volumen:
671.96K
Relative Volume:
0.78
Marktkapitalisierung:
$256.92M
Einnahmen:
$893.00K
Nettoeinkommen (Verlust:
$-151.61M
KGV:
-3.5132
EPS:
-0.5152
Netto-Cashflow:
$-135.31M
1W Leistung:
+11.73%
1M Leistung:
-21.30%
6M Leistung:
-37.59%
1J Leistung:
+202.02%
1-Tages-Spanne:
$1.81
$1.94
1-Wochen-Bereich:
$1.66
$1.94
52-Wochen-Spanne:
$0.4603
$7.13
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Compare PROK vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PROK
Prokidney Corp
|
1.81 | 269.69M | 893.00K | -151.61M | -135.31M | -0.5152 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-30 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-30 | Eingeleitet | JP Morgan | Neutral |
| 2024-09-10 | Eingeleitet | Guggenheim | Buy |
| 2024-03-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-07-25 | Eingeleitet | BTIG Research | Buy |
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
April 2026 Penny Stock Highlights - simplywall.st
Hennion & Walsh Asset Management Inc. Has $3.37 Million Holdings in ProKidney Corp. $PROK - MarketBeat
Analysis Recap: What is the long term forecast for ProKidney Corp stockTrade Performance Summary & Low Drawdown Trading Strategies - baoquankhu1.vn
What Makes ProKidney Corp. (PROK) So Attractive - Yahoo Finance
Sell Signal: Will ProKidney Corp benefit from geopolitical trendsTrade Risk Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Revenue Check: Does ProKidney Corp outperform in volatile markets2026 Drop Watch & Consistent Profit Trading Strategies - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Shares Up 5.9%Here's Why - MarketBeat
5 Best Penny Stocks That Could Triple Your Money - Insider Monkey
Investment Report: What are the future prospects of ProKidney Corp2026 Earnings Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
ProKidney (MEX:PROK) PB Ratio : (As of Mar. 27, 2026) - GuruFocus
ProKidney hires chief commercial officer as key clinical test results near - Winston-Salem Journal
ProKidney names Greg Madison as chief commercial officer By Investing.com - Investing.com Australia
ProKidney appoints Greg Madison as chief commercial officer - TipRanks
ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer - Bitget
ProKidney names Greg Madison as chief commercial officer - Investing.com
ProKidney expands senior leadership team with appointment of Greg Madison as chief commercial officer - marketscreener.com
Prokidney Expands Senior Leadership Team With Appointment Of Greg Madison As Chief Commercial Officer - TradingView
ProKidney (NASDAQ:PROK) Trading Down 7.6%Here's What Happened - MarketBeat
Q2 Earnings Forecast for ProKidney Issued By HC Wainwright - MarketBeat
ProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Insider Sell: Does ProKidney Corp offer margin of safety2026 Outlook & Capital Efficiency Focused Ideas - baoquankhu1.vn
ProKidney A: Fundamental Analysis and Financial Ratings | PROK | KYG7S53R1049 - marketscreener.com
ProKidney (NASDAQ:PROK) Cut to Sell at Wall Street Zen - MarketBeat
ProKidney narrows loss to $150M as it eyes crucial kidney treatment trial results - The Business Journals
Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Equities Analysts Set Expectations for ProKidney Q1 Earnings - MarketBeat
Guggenheim Sticks to Its Buy Rating for ProKidney (PROK) - The Globe and Mail
ProKidney’s Greensboro Facility Could Shield It From Looming Tariff Risks—But Time Is Short - Bitget
Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability - TipRanks
ProKidney Makes Major Wager on U.S. Tariff Relief—Does Consistent Policy Support a $485M Risk? - Bitget
ProKidney ends fiscal 2025 with bigger loss, larger revenue stream - Winston-Salem Journal
ProKidney: Extended Development Timeline and Deferred Catalysts Support Balanced Hold Rating - TipRanks
ProKidney (NASDAQ:PROK) Raised to "Strong-Buy" at Jefferies Financial Group - MarketBeat
BofA reiterates ProKidney stock Underperform rating at $1 target By Investing.com - Investing.com South Africa
ProKidney Corp. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
BofA reiterates ProKidney stock Underperform rating at $1 target - Investing.com
ProKidney (NASDAQ:PROK) Releases Earnings Results - MarketBeat
ProKidney Reports Full Year 2025 Financial Results and Business Highlights - Bitget
PROK: FDA alignment, strong clinical progress, and cash runway into 2027 despite ongoing losses - TradingView
ProKidney (Nasdaq: PROK) details 2025 loss and cash runway into 2027 - Stock Titan
ProKidney (PROK) advances Phase 3 rilparencel program for diabetic CKD - Stock Titan
ProKidney’s High Cash Usage Dims Pipeline Hopes—Investors Brace for Funding Shortfall Before 2027 Results - bitget.com
ETF Watch: How volatile is ProKidney Corp stock2026 PreEarnings & Entry and Exit Point Strategies - baoquankhu1.vn
Aug Update: Why is ProKidney Corp stock going downRisk Management & AI Powered Market Entry Ideas - baoquankhu1.vn
ProKidney (NASDAQ:PROK) Stock Price Down 4.7%Time to Sell? - MarketBeat
Dividend Watch: Is ProKidney Corp stock undervalued right now2026 Update & Real-Time Price Movement Reports - baoquankhu1.vn
ProKidney’s Unclear Messages Leave Traders Puzzled - Bitget
Portfolio Shifts: Is ProKidney Corp impacted by rising ratesOptions Play & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Meet the Biotech Stock That Rocketed 775% Higher - msn.com
Prokidney Corp expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Momentum Shift: Is ProKidney Corp stock undervalued right nowWeekly Trade Recap & Reliable Volume Spike Alerts - baoquankhu1.vn
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prokidney Corp-Aktie (PROK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pereira Brian JG | Director |
Nov 12 '25 |
Sale |
2.72 |
255,026 |
694,515 |
54,333 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):